INFUSION Magazine

PROFESSIONAL/COGNITIVE PHARMACY SERVICES

Barrell JM. Grassroots advocacy: Even in Washington, it's the people that matter. 2000;6(4):11-5.

Barrell JM. Rising to address the pharmacist shortage. 2002;8(2);16-22.

Borfitz D. Professional services reimbursement: Can community pharmacists show us the way? 1999;6(2):23-7.

Borfitz D. Home infusion's future lies in distinguishing product from service. 1999;6(2):31-5.

Counce J. They didn’t teach this in pharmacy school: Home infusion practice setting offers unique challenges, rewards.2007:13(1);18-28.

Counce J and Kramer N. Case management of the challenging IgG patient: Clinical considerations for the most effective and safe therapy.2009:15(4);S1-S8.

Counce J. Beyond bedside manner: Supporting the emotional needs of patients receiving alternate-site infusion therapy. 2011; 17(5):12-19.

Counce J. The secret to patient satisfaction isn't just what providers do—It's how they do it! 2011; 17(5):28-34.

Dobson A, Lamphere J, Koenig L, and Babcock J. Impact of proposed AWPs on the provision of home care drug therapies to medicare and medicaid patients. 2001;7(2):22-7.

Erramuzpe K and Rout T. Boning up on bacteria: Understanding and outsmarting the enemy. 2001;7(7):18- 26.

Franklin DM. In the beginning: The establishment of reimbursement for pharmacy-based services. 2006.12(2):35-8.

Franklin DM. Pricing pharmacy services. 2006. 12(4):39-43.

Kaplan LK. Recognition and reimbursement for infusion professional services: A roadmap for the association. 1999;6(2):43-8.

Kaplan LK. PBMs in home infusion. 1999;6(3):27-31.

Kaplan LK. How to use the new HCPCS home infusion codes. 2001;8(2):24-8.

Kaplan L. Patient safety under the new Medicare prescription drug benefit. 2006:12(1):26-31.

Klotz RS. Maximizing the productivity of your professional staff. 2000;6(5):14-8.

Kramer N and Counce J. Home Infusion and the Elderly Patient: Considerations for Safe and Effective Care. 2010; 16(5):27-38.

Leone M and Counce J. Medical marijuana: Implications for home infusion providers. 2010; 16(6):27-37.

Lima H. Looking down the pipeline: A biotech market update. 2000;7(1):14-9.

Massari A. Compassion as a healing tool. 2011; 17(5):20-1.

McKinnon BT. Synagis®: A clinical overview. 2000;7(1):26-32.

NHIA. Bayer direct: New distribution program creates unanswered questions. 1999;6(3):16-21.

NHIA. Exclusive distribution: Hotly contested, and not sustained. 1999;6(3):22-6.

Nowobilski-Vasilios A and Poole S. Interdisciplinary collaboration: Perceptions and possibilities. 2001;7(7):14-7.

Orange J. Optimizing immunoglobulin therapy in the treatment of primary immunodeficiency disease. 2011; 17(5):Supp.S1-S12.

Rappa E and Ness S. Balancing medication access and risk: What the FDA's REMS programs mean for infusion pharmacy. 2011; 17(6):16-23.

Rollins CJ. Aluminum content in parenteral products: What clinicians should know about preventing toxicity. 2005:11(1):27-35.

Rollins G. The nurse pharmacist connection. 2000;6(6):15-8.

Rollins G. The Medicaid AWP challenge: Providers respond. 2000;7(1):36-.9

Schumann K. Healthier babies: A valuable outcome. 2000;7(1):20-5.

Sirois PC and Maksym CJ. Operational efficiency: Optimizing pharmacy support staff can save time and resources. 2003;9(5):12-17.

Wingert S. Meeting the Unique Needs of the Pediatric Home Care Patient: Lessons from a Full-Service Provider. 2010; 16(5):21-6.